<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006258</url>
  </required_header>
  <id_info>
    <org_study_id>CHLA-NYU-0002H</org_study_id>
    <secondary_id>CDR0000068192</secondary_id>
    <secondary_id>NYU-0027H</secondary_id>
    <secondary_id>NCI-G00-1852</secondary_id>
    <nct_id>NCT00006258</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma</brief_title>
  <official_title>Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
      Combining more than one drug or combining chemotherapy with radiation therapy may kill more
      tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by
      radiation therapy in treating patients who have surgically resected, newly diagnosed
      medulloblastoma or supratentorial primitive neuroectodermal tumor, or incompletely resected
      ependymoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the toxicity of adjuvant dose-intensive induction chemotherapy with cisplatin,
           vincristine, cyclophosphamide, and etoposide with or without methotrexate followed by
           standard radiotherapy in patients with surgically resected, newly diagnosed high stage
           medulloblastoma or supratentorial primitive neuroectodermal tumor, or incompletely
           resected ependymoma.

        -  Determine the response rate, time to progression, overall survival, and pattern of
           failure in these patients treated with this regimen.

      OUTLINE: Patients receive dose-intensive induction chemotherapy consisting of cisplatin IV
      over 6 hours on day 0; vincristine IV on days 0, 7, and 14; and etoposide and
      cyclophosphamide IV over 1 hour on days 1 and 2. Patients with M1+ disease (i.e., evidence of
      dissemination beyond primary tumor site) also receive methotrexate IV over 4 hours on day 3.
      Patients receive filgrastim (G-CSF) subcutaneously daily beginning on day 7 and continuing
      until blood counts recover. Chemotherapy continues every 21-28 days for a total of 3 courses
      in the absence of disease progression or unacceptable toxicity. Patients then undergo
      radiotherapy 5 days a week for 6.5 weeks beginning 3-6 weeks after completion of
      chemotherapy.

      Patients are followed at 6 weeks, then every 3 months for 2 years, every 4 months for 1 year,
      every 6 months for 1 year, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 6-20 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1997</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histological confirmation of one of the following:

               -  High stage medulloblastoma with neuraxis dissemination (Chang stage M1 or
                  greater)

               -  Primitive neuroectodermal tumor

               -  Ependymoma

                    -  Incompletely resected on postoperative MRI or neurosurgical report

          -  Definitive prior surgery within 42 days of study

        PATIENT CHARACTERISTICS:

        Age:

          -  10 to 65

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin less than 1.5 mg/dL

          -  SGPT less than 2.5 times upper limit of normal

        Renal:

          -  Creatinine clearance greater than 60 mL/min

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Prior corticosteroids allowed

          -  No concurrent corticosteroids as antiemetics

        Radiotherapy:

          -  No prior radiotherapy

        Surgery:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan L. Finlay, MB, ChB</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-1320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dhodapkar K, Dunkel IJ, Gardner S, Sapp M, Thoron L, Finlay J. Preliminary results of dose intensive pre-irradiation chemotherapy in patients older than 10 years of age with high risk medulloblastoma and supratentorial primitive neuroectodermal tumors. Med Pediatr Oncol. 2002 Jan;38(1):47-8.</citation>
    <PMID>11835236</PMID>
  </results_reference>
  <verification_date>December 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <keyword>adult supratentorial primitive neuroectodermal tumor (PNET)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

